Arzneimittel-Forschung 1994-10-01

Thymopentin treatment of rheumatoid arthritis.

E Sundal, D Bertelletti

Index: Arzneimittelforschung 44(10) , 1145-9, (1994)

Full Text: HTML

Abstract

Although the etiology of rheumatoid arthritis (RA) is unknown, there is solid evidence that immunological factors play a pivotal role in its pathogenesis. It seems that a hyporeactivity of local (intraarticular) T-suppressor cells would permit an excessive immune response that ultimately leads to the classical symptoms and signs of inflammation and cartilage damage. Thymopentin is a synthetic pentapeptide (Arg-Lys-Asp-Val-Tyr) which represents the active biologic site (sequence 32-36) of the native thymic hormone thymopoietin, containing 49 amino acids. Thymopoietin and thymopentin have been shown to possess immuno-normalizing properties in a number of animal model systems. Low concentrations of the hormone characteristically stimulate the OKT4-positive cells, whereas higher concentrations additionally induce stimulation of OKT8-positive cells. This report summarizes the clinical experience collected by Italian investigators, and discusses the results with a view to previously published papers.


Related Compounds

  • Thymopentin

Related Articles:

Stability and aerosolization of pressurized metered dose inhalers containing thymopentin nanoparticles produced using a bottom-up process.

2012-05-10

[Int. J. Pharm. 427(2) , 385-92, (2012)]

Separation and purification of thymopentin with molecular imprinting membrane by solid phase extraction disks.

2015-01-01

[J. Pharm. Biomed. Anal. 102 , 137-43, (2014)]

[Vulvar lesions caused by Papillomavirus (HPV): effectiveness of thymopentin (Syntomoduline). First results and experiences].

1991-01-01

[Minerva Ginecol. 43(1-2) , 53-6, (1991)]

Peptides and polypeptides as modulators of the immune response: thymopentin--an example with unknown mode of action.

1999-06-01

[Pharm. Acta Helv. 73(6) , 265-73, (1999)]

Immunomodulation with thymopentin: in vitro studies.

1989-01-01

[Med. Oncol. Tumor Pharmacother. 6(1) , 19-23, (1989)]

More Articles...